The latest (March 2024) clinical guidelines from the American College of Physicians (ACP) recommend adding a glucagon-like peptide-1 receptor agonist (GLP-1RA) medication to metformin for patients with T2DM who are not achieving adequate blood sugar control with metformin alone [11]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.